Company overview
Flare Therapeutics is a clinical-stage biotechnology company developing small molecule precision medicines that target transcription factors, initially focused on oncology including urothelial and prostate cancers. Their lead program, FX-909, is an oral PPARG inhibitor in Phase 1 trials for advanced urothelial cancer, with a collaboration to combine it with Merck's KEYTRUDA. They leverage an integrated platform combining pocket mapping, structural biology, and chemoproteomics to drug previously undruggable targets, supported by partnerships with Roche and others.
Flare - Flare Therapeutics is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include flare therapeutics, transcription factor drugs, precision oncology, pparg inhibitor, fx-909, urothelial cancer.
Structured facts
- Website
- https://www.flaretx.com
- Markets served
- United States & Americas
- Keywords
- flare therapeutics, transcription factor drugs, precision oncology, pparg inhibitor, fx-909, urothelial cancer
Products & technologies
Therapeutic areas
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What is Flare Therapeutics' main therapeutic focus and pipeline stage?
- Flare focuses on precision oncology, with clinical-stage programs like FX-909 (PPARG inhibitor in Phase 1 for urothelial cancer) and FX-111 (AR degrader in IND-enabling studies for prostate cancer), plus earlier-stage oncology targets.
- What technology platform does Flare use for drug discovery?
- Flare's platform integrates pocket mapping via genetics and structural biology with chemoproteomics using proprietary electrophilic libraries to identify ligands for undruggable transcription factors.
- What partnerships and collaborations does Flare have?
- Flare has a clinical trial collaboration with Merck for FX-909 + KEYTRUDA in urothelial cancer, a discovery collaboration with Roche targeting oncology transcription factors (up to $1.8B milestones), and partnerships like Caris Life Sciences.
Related editorial coverage
- FDA Companion Diagnostic Policies: Market Evolution in Precision Oncology
- Next-Generation Sequencing MEA: Impact on Precision Oncology Treatment Selection
- AACR 2026: ctDNA, Immunotherapy, and KRAS Target Breakthroughs
Explore lab tools and QA/QC resources for R&D teams.
